Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566107 | 0.78 | HSD17B10 (0.39) | PARP1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL10836335 | 0.78 | CYP2D6 (0.43) | PARP1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL7093772 | 0.71 | BCAT2 (0.47) | PARP1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL2289138 | 0.69 | CYP2D6 (0.50) | HSD17B10KDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL3726837 | 0.69 | HTT (0.53) | HSD17B10KDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL8668737 | 0.67 | TSHR (0.46) | HSD17B10KDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL27514150 | 0.67 | GAA (0.53) | PARP1HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL8202219 | 0.67 | CYP2D6 (0.48) | HSD17B10KDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL1276497 | 0.66 | CYP2D6 (0.41) | HSD17B10KDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL147847 | 0.66 | ALDH1A1 (0.69) | HSD17B10KDM4EALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600440-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | Sienna Biopharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020023389-A1 | REDUCED EXPOSURE COMPOSITIONS MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2018175340-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175301-A1 | POLYMER CONJUGATE OF MONTESANIB WITH REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175302-A1 | POLYMER CONJUGATES TARGETING C-SRC WITH REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-2166860-B1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA CELLULAR THERAPIES INC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160075683-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | LI PENG (US) | 2016-03-17 | — | — | US | disclosed |
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA CELLULAR THERAPIES INC (US) | 2015-09-17 | — | — | US | disclosed |
| US-9062023-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9056837-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20100184778-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES INC. | 2010-07-08 | — | — | US | disclosed |
| US-20100111876-A1 | USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE | GUERBET (FR) | 2010-05-06 | — | — | US | disclosed |
| EP-2166860-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | Intra-Cellular Therapies, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2166858-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | Intra-Cellular Therapies, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7687512-B2 | 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; for neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| WO-2008153974-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153959-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20070129389-A1 | Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders | NOVARTIS AG (CH) | 2007-06-07 | — | — | US | disclosed |
| WO-2005039586-A1 | USE OF PYRIDINYL-PYRIMIDINYLAMINO-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF AMYLOID RELATED DISORDERS | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075683-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | APP, BACE1, PYGB | PARP1 2190/4885HSD17B10 2062/4885KDM4E 2945/4885 |
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | PARP1 3294/4885HSD17B10 1340/4885KDM4E 3588/4885 |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | PARP1 3211/4885HSD17B10 1420/4885KDM4E 3515/4885 |
| US-20100184778-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | APP, PYGB, BACE1 | PARP1 2435/4885HSD17B10 2081/4885KDM4E 3014/4885 |
| US-20100111876-A1 | USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, APP | PARP1 3700/4885HSD17B10 3344/4885KDM4E 4332/4885 |
| US-20070129389-A1 | Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders | TIE1, ABL2, FYN | PARP1 529/4885HSD17B10 4548/4885KDM4E 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.